About PlantForm
PlantForm's mission is to provide low-cost subsequent-entry-biologic (SEB) antibody drugs to help people fight cancer and other critical illnesses.
Antibody therapies are revolutionizing how we treat disease. The problem is that the drugs now on the market are also extremely expensive. Access to more affordable alternatives is a priority for patients, health-care providers and insurers.
PlantForm's proprietary, plant-based technology platform was developed at the University of Guelph by Dr. J. Christopher Hall, the Canada Research Chair in Recombinant Antibody Technology.
This platform — protected with patent filings — is designed to allow PlantForm to produce fully active versions of approved antibody drugs for as little as 10 per cent of the manufacturing cost of brand-name products.
Fighting breast cancer: Our first product will be an SEB version of the breast-cancer drug Herceptin, the brand name for trastuzumab.
We also plan to develop and produce SEBs for other cancer and inflammatory-disease drugs that are forecast to have combined annual global sales of $35.3 billion by 2013.
Our Commitment
PlantForm will produce low-cost SEB antibody drugs in an environmentally and socially responsible manner to improve the quality of life and survival of patients with cancer and other critical illnesses.